Sangamo Therapeutics(SGMO) Prnewswire·2025-01-03 02:05Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc regarding potential securities fraud or unlawful business practices [1] Collaboration Termination - Pfizer decided to return the development and commercialization rights of hemophilia A gene therapy candidate giroctocogene fitelparvovec to Sangamo, despite the therapy being in phase 3 [2] - Sangamo expressed surprise and disappointment at Pfizer's decision to end the collaboration close to anticipated Biologics License Application and Marketing Authorisation Application submissions, expected in early 2025 [3] - The collaboration and license agreement with Pfizer will terminate on April 21, 2025, with Pfizer required to transition the giroctocogene fitelparvovec program back to Sangamo [4] Market Reaction - Sangamo's stock price fell sharply during intraday trading on December 31, 2024 following the announcement of Pfizer's decision [5] About Pomerantz LLP - Pomerantz LLP is a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages awards for class members [6]